

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Curriculum Vitae - Summary Page - Neil M. Bressler, M.D.

Title: James P. Gills (inaugural) Professor of Ophthalmology – Johns Hopkins

Family: [-----]
[-----]

Peer-Reviewed Publications: 223

Other Publications: 30 book chapters; *Editor-in-Chief* of *The Wilmer Retina Update: 1995-2000*; *Advanced Studies in Ophthalmology* (Editor-in-Chief): Present.

Major Research: Design and implement clinical trials evaluating retinal diseases. Currently, Previous *Study Chair* of 6 multicenter randomized clinical trials: 3 sponsored by the National Eye Institute of the National Institutes of Health; 3 sponsored by industry. Also, *Network Chair* of the Diabetic Retinopathy Clinical Research Network (DRCR.net) involving 11 randomized clinical trials and observation studies sponsored by the National Eye Institute of the National Institutes of Health.

Education: Former Director: Retinal Fellowship Program and Residency Retina Rotation
Participant: Medical student required clerkships and electives
Mentor: School of Public Health PhD candidates
Director: Annual Continuing Medical Education Courses at Hopkins

Clinical Practice: National and international referral for retinal diseases at Wilmer

Editorial Boards: *Archives of Ophthalmology*; *Retina*;
Advanced Studies in Ophthalmology (*Founding Editor and Editor-in-Chief*)

Major National Advisories:

Chair, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of National Institutes of Health
Ophthalmic Devices Panel of the Medical Devices Advisory Committee for the Center for Devices and Radiologic Health, Food and Drug Administration
U.S. Pharmacopoeia Expert Committee
Carotene in Age-Related Eye Disease Study (CAREDS) Scientific Advisory Board for National Eye Institute

University Advisories: Chair, Dean's Committee on Outside Interests

Recent Honors:

The Macula Society Rosenthal Award and Lecture
The Society of Heed Fellows Award
Inaugural Recipient of the Neil R. Miller Medical Student Teaching Award
The Alvaro Rodriguez Gonzalez Lecture and Gold Medal
Saudi Ophthalmology Society Medal
National Society of Southern Dames Award
The Macula Society J. Donald M. Gass Medal

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

American Society of Retinal Specialists Award
Helen Keller Foundation Award and Lecture
The Macula Society Research and Education Award
American Academy of Ophthalmology Senior Achievement Award

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

BIOGRAPHICAL INFORMATION

Born: [-----]

[-----]

-----]

[-----]
[-----]

Address

Office: 550 North Broadway, Suite 115
Baltimore, MD 21205-2002
Phone: 1-410-955-8342
FAX: 1-410-955-0845
[-----]

Home: [-----]

-----]

EDUCATION

Undergraduate: University of Michigan, Ann Arbor, MI - Bachelor of Science – [--]

Medical School: The Johns Hopkins University School of Medicine, Baltimore, MD – [--]

Internship/Internal Medicine Fellowship: Johns Hopkins Hospital - Department of Medicine – [-----]

Ophthalmology Residency: Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, MA – [-----]

Retinal Fellowship: Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD – [-----]

ACADEMIC APPOINTMENTS

July 1, 1987 - June 30, 1988: Harvard Medical School, Department of Ophthalmology, Instructor of Ophthalmology

July 1, 1988 - October 1991: Johns Hopkins University School of Medicine, Department of Ophthalmology, Assistant Professor of Ophthalmology

October 1991 - June 1997: Johns Hopkins University School of Medicine, Department of Ophthalmology, Associate Professor of Ophthalmology

July 1997 - Present: Johns Hopkins University School of Medicine, Department of Ophthalmology, Professor of Ophthalmology

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

April 2000 - Present: Johns Hopkins University School of Medicine, Department of Ophthalmology,
The James P. Gills Professor of Ophthalmology (inaugural recipient)

PRIMARY HOSPITAL APPOINTMENTS

July 1, 1987 - June 30, 1988: Massachusetts Eye and Ear Infirmary, Assistant in Ophthalmology

July 1, 1988 - October, 1991: Johns Hopkins Hospital, Assistant Professor of Ophthalmology

October 1991 - June 1997: Johns Hopkins Hospital, Department of Ophthalmology, Associate Professor
of Ophthalmology

June 1997 - Present: Johns Hopkins Hospital, Department of Ophthalmology, Professor of
Ophthalmology

BOARD CERTIFICATIONS

Ophthalmology – [-----]

HONORS

[----]: Class Honors - University of Michigan
[--]: Angell Scholar - University of Michigan
[---]: Bachelor of Science with High Distinction and Honors in Zoology
[--]: Phi Beta Kappa
[--]: Paul Ehrlich Award in Clinical Investigation - Johns Hopkins Medical School
1986: Heed Fellowship
1987: Heed/Knapp Fellowship
1993: American Academy of Ophthalmology Honor Award
1995: Research to Prevent Blindness Olga Keith Weiss Scholars Award
1997: The Macula Society Rosenthal Award and Lecture
1999: The Society of Heed Fellows Award
2000: Inaugural Recipient of the Neil R. Miller Medical Student Teaching Award
2000: Inaugural Recipient of the James P. Gills Professorship of Ophthalmology
2000: National Society of Southern Dames Award
2001: The Alvaro Rodriguez Gonzalez Lecture and Gold Medal
2001: Saudi Ophthalmology Society Medal
2003: The Macula Society J. Donald M. Gass Medal
2003: Neil R. Miller Medical Student Teaching Award
2003: American Society of Retinal Specialists Award
2004: Helen Keller Foundation Award and Lecture
2004: The Macula Society Research and Education Award
2004: The American Academy of Ophthalmology's Senior Achievement Award

PEER-REVIEWED PUBLICATIONS

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

1. Bressler NM, Broekman MJ, Marcus AJ. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. *Blood* 1979;53:167-178.
2. Bressler SB, Bressler NM, Fine SL et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. *Am J Ophthalmol* 1982;93:157-163.
3. Fine SL, Bressler NM, Bressler SB, Murphy RP: Macular degeneration update 1983. *Trans Pac Coast Oto-Ophthalmol Soc* 1982;63:35-40.
4. Bressler SB, Bressler NM, Fine SL et al. Subfoveal neovascular membranes in senile macular degeneration: Relationship between membrane size and visual prognosis. *Retina* 1983;3:7-11.
5. Bressler NM, Gragoudas ES. Neovascularization of the optic disk associated with atypical retinitis pigmentosa. *Am J Ophthalmol* 1985;100:431-433.
6. Bressler NM, Gragoudas ES. Retinitis pigmentosa and retinal neovascularization. *Ophthalmology* 1987;94:895.
7. Bressler NM, Bressler SB, Gragoudas EG. Clinical characteristics of choroidal neovascular membranes. *Arch Ophthalmol* 1987;105:209-213.
8. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. *Surv Ophthalmol* 1988;32:375-413.
9. Bressler SB, Bressler NM, Seddon JS, et al. Interobserver and intraobserver reliability in the clinical classification of drusen. *Retina* 1988;8:102-108.
10. Bressler NM, Bressler SB, Seddon JS et al. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. *Retina* 1988;8:109-114.
11. Bressler NM, Frost L, Bressler SB, Fine SL. Natural course of poorly defined choroidal neovascularization in macular degeneration. *Arch Ophthalmol* 1988;106:1537-1542.
12. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. *Arch Ophthalmol* 1989;107:847-852.
13. Sunness JS, Massof RW, Bressler NM, Bressler SB. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. *Ophthalmology* 1989;96:375-381.
14. West S, Bressler NM, Bressler SB et al. Exposure to sunlight and other risk factors associated with age-related macular degeneration. *Arch Ophthalmol* 1989;107:875-879.
15. Sunness JS, Massof RW, Bressler NM, Bressler SB. S cone pathway sensitivity in eyes with high risk and low risk drusen characteristics. *Applied Optics* 1989;28:1158-1164.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

16. Chamberlin JA, Bressler NM, Bressler SB, et al. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. *Ophthalmology* 1989;96:1526-1534.
17. Macular Photocoagulation Study Group (prepared by Maguire MG, Folk JC, Singerman LJ, Schachat AP, Blackhurst DW, Chamberlin JA, Bressler NM, Fine SL, Hawkins BS, Elman MJ). Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. *Arch Ophthalmol* 1989;107:344-352.
18. Maguire MG, Folk JC, Singerman LJ, Schachat AP, Blackhurst DW, Chamberlin JA, Bressler NM, Fine SL, Hawkins BS, Elman MJ, Macular Photocoagulation Study Group. Response to Letter: Partial ablation of neovascular membranes involving the fovea. *Arch Ophthalmol* 1989;107:955-956.
19. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. *Arch Ophthalmol* 1990;108:816-824.
20. Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions: results of a randomized clinical trial. *Arch Ophthalmol* 1990;108:832-837.
21. Macular Photocoagulation Study Group (prepared by Maguire MG, Blackhurst DW, Alexander J, Bressler NM, Hawkins BS, Fine SL). Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 1990;108:825-831.
22. Bressler SB, Maguire MG, Bressler NM, Fine SL, Macular Photocoagulation Study Group: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. *Arch Ophthalmol* 1990;108:1442-1447.
23. Bressler NM, Finkelstein D, Sunness J, et al. Retinal pigment epithelial tears through the fovea with preservation of good visual acuity. *Arch Ophthalmol* 1990;108:1694-1697.
24. Taylor HR, Muñoz MS, West S, Bressler NB, Rosenthal FS, Bressler SB. Visible light and risk of age-related macular degeneration. *Tr Am Ophth Soc* 1990;88:163-178.
25. Bressler NM, Bressler SB, Alexander J, et al. Loculated fluid: A previously undescribed angiographic finding in macular degeneration. *Arch Ophthalmol* 1991;109:211-215.
26. Repka MX, Bressler NM, D'Anna S. Primate model of macular cysts. *Ophthalmology* 1991;98:535-540.
27. Kwiterovich KA, Fine SL, Maguire MG, Bressler NM, Bressler SB, Murphy RP. Frequency of adverse systemic reactions after fluorescein angiography: Results of a prospective study. *Ophthalmology* 1991;98:1139-1142.
28. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after five years: Results from randomized clinical trials. *Arch Ophthalmol* 109:1109-1114;1991.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

29. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1991;109:1219-1231.
30. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1991;109:1232-1241.
31. Macular Photocoagulation Study Group (prepared by: Bressler NM, Alexander J, Bressler SB, et al). Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. *Arch Ophthalmol* 1991;109:1242-1257.
32. Macular Photocoagulation Study Group (prepared by Fine SL, Hawkins BS, Maguire MG, Bressler NM, et al). Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 1991;109:614-615.
33. Folk JC, Blackhurst DW, Alexander J, Elman MJ, Phillips DA, Macular Photocoagulation Study Group. Pretreatment fundus characteristics as predictors of recurrent choroidal neovascularization. *Arch Ophthalmol* 1991;109:1193-1194.
34. Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye. *Arch Ophthalmol* 1992;110:99-106.
35. Bressler SB, Silva JC, Bressler NM, Alexander JA, Green WR. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. *Arch Ophthalmol* 1992;110:827-832.
36. Lim JI, Bressler NM. Atypical parafoveal telangiectasis with subsequent anterior and posterior segment neovascularization. *Retina* 1992;12:351-354.
37. Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. *Am J Ophthalmol* 1993;116:414-423.
38. Fine SL, Wood WJ, Isernhagen RD, Singerman LF, Bressler NM, Folk JC, Kimura AE, Fish GE, Maguire MG, Alexander J. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: Results of a pilot randomized clinical trial. *Arch Ophthalmol* 1993;111:19-20.
39. Bressler NM, Alexander J, Hawkins BS, Maguire MG, Fine SL, for the Macular Photocoagulation Study Group. Response to letter: Subfoveal neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1993;111:901.
40. Macular Photocoagulation Study Group (prepared by Burgess DB, Hawkins BS, Jefferys JL, Bressler NM, et al). Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. *Arch Ophthalmol* 1993;111:1189-1199.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

41. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: Updated findings from two clinical trials. *Arch Ophthalmol* 1993;111:1200-1209.
42. West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler SB, Bressler NM. Are antioxidants or supplements protective for age-related macular degeneration? *Arch Ophthalmol* 1994;112:222-227.
43. Macular Photocoagulation Study Group. Laser photocoagulation of juxtafoveal choroidal neovascularization: Five-year results from randomized clinical trials. *Arch Ophthalmol* 1994;111:500-509.
44. MacCumber MW, Dastgheib K, Bressler NM, Chan C, Harris M, Fine S, Green WR. Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. *Retina* 1994;14:143-152.
45. Schein OD, West S, Munoz B, Vitale S, Maguire MG, Taylor HR, Bressler NM. Cortical lenticular opacification: distribution and location in a longitudinal study. *Invest Ophthalmol Vis Sci* 1994;35:363-366.
46. Edwards MG, Schachat AP, Bressler SB, Bressler NM. Outcome of cataract surgery performed to permit diagnosis, determine eligibility for laser therapy, or perform laser therapy of retinal disorders. *Am J Ophthalmol* 1994;118:440-444.
47. Macular Photocoagulation Study Group (prepared by Maguire MG, Klein ML, Olk RJ, Phillips DA, Alexander J, Javornik NB, Hiner C, Marsh MJ, Bressler NM et al). Persistent and recurrent choroidal neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. *Arch Ophthalmol* 1994;112:489-499;.
48. Pieramici DJ, Bressler NM, Bressler SB, Schachat AP. Choroidal neovascularization in black patients. *Arch Ophthalmol* 1994;112:1043-1046.
49. Bressler SB, Jefferys JL, Bressler NM, Alexander J, et al, for the Macular Photocoagulation Study Group. Evaluation of green versus red laser for photocoagulation of subfoveal choroidal neovascularization in the Macular Photocoagulation Study. *Arch Ophthalmol* 1994;112:1176-1184.
50. Maguire MG, Fine SL, Folk JC, Bressler NM et al for the Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: The influence of initial lesion size and initial visual acuity. *Arch Ophthalmol* 1994;112:480-488.
51. West SK, Bressler SB, Bressler NM, Vitale S. Are antioxidants or supplements protective for age-related macular degeneration? In reply to letter: *Arch Ophthalmol* 1994;112:730.
52. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. *Retina* 1994;14:130-142.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

53. Dyer DS, Bressler SB, Bressler NM. The role of laser wavelength in the treatment of vitreoretinal diseases. *Curr Opin Ophthalmol* 1994;5:35-43.
54. Sykes SO, Bressler NM, Maguire MG, Schachat AP, Bressler SB. Detecting recurrent choroidal neovascularization: comparison of clinical examination with and without fluorescein angiography. *Arch Ophthalmol* 1994;111:1561-1566.
55. Macular Photocoagulation Study Group (prepared by Marsh MJ, Fine SL, Alexander J, Schachat AP, Maguire MG, Bressler NM, et al). Laser photocoagulation for neovascular lesions nasal to the fovea associated with ocular histoplasmosis or idiopathic causes. *Arch Ophthalmol* 1995;113:56-61.
56. Maguire MG, Fine SL, Folk JC, Bressler NM, et al. Treatment of subfoveal choroidal neovascularization: In reply to letter. *Arch Ophthalmol* 1995;113:138.
57. Macular Photocoagulation Study Group (prepared by Maguire MG, Alexander, J, Bressler NM, Schachat AP). The influence of treatment coverage on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1995;113:190-194.
58. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. *Surv Ophthalmol* 1995;39:5:367-374.
59. Sunness JS, Bressler NM, Maguire MG. Scanning laser ophthalmoscopic analysis of the pattern of visual loss in age-related geographic atrophy of the macula. *Am J Ophthalmol* 1995;119:143-151.
60. West S, Munoz B, Schein O, Vitale S, Maguire M, Taylor H, Bressler NM. Cigarette smoking and risk for progression of nuclear opacities. *Arch Ophthalmol* 1995;113:1377-1380.
61. Bressler NM, Munoz B, Maguire MG, Vitale S, Schein OD, Taylor HR, West S. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. *Arch Ophthalmol* 1995;113:301-308.
62. Friberg TR, Braunstein RA, Bressler NM, Munson, RS. Sudden visual loss associated with sexual activity. *Arch Ophthalmol* 1995;113:378-342.
63. Bressler NM, Bressler SB. Preventative ophthalmology: Age-related macular degeneration. *Ophthalmology* 1995;102:1206-1211.
64. Zimmer-Galler IE, Bressler NM, Bressler SB. Treatment of choroidal neovascularization: updated information from recent Macular Photocoagulation Study Group reports. *Int Ophthalmol Clin* 1995;35:37-57.
65. Dyer DS, Brant AM, Schachat AP, Bressler SB, Bressler NM. Angiographic features and outcome of questionable recurrent choroidal neovascularization. *Am J Ophthalmol* 1995;120:497-505.
66. Bressler NM. Submacular surgery: Are randomized trials necessary? *Arch Ophthalmol* 1995;113:1557-1560.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

67. Macular Photocoagulation Study Group (prepared by Wilkinson CP, Hawkins BS, Javornik NB, Newhouse MM, Keller JA, Bressler NM, et al). Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1996;114:677-688.
68. Macular Photocoagulation Study Group (prepared by Bressler NM, Marsh MJ, Maguire MG, Alexander J, Phillips DA, et al). Occult choroidal neovascularization: Influence on visual outcome in patients with age-related macular degeneration. *Arch Ophthalmol* 1996;114:400-412.
69. Bressler NM, Bressler SB. Indocyanine green angiography: can it help preserve the vision of our patients? *Arch Ophthalmol* 1996;114:747-749.
70. Jabs DA, Dunn JP, Enger C, Forman M, Bressler NM, Charache P. Cytomegalovirus retinitis and viral resistance: Prevalence of resistance at diagnosis. *Arch Ophthalmol* 1996;114:809-814.
71. Bressler NM, O'Brien TP. Meeting report of the Hawaii '96 meeting. *Arch Ophthalmol* 1996;114:894.
72. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. *Retina* 1996;16:183-189.
73. Kiri A, Dyer DS, Bressler NM, Bressler SB, Schachat AP. Detection of diabetic macular edema: Nidek 3Dx stereophotography compared with fundus biomicroscopy. *Am J Ophthalmol* 1996;122:654-662.
74. Bressler NM, Maguire MG, Murphy, PL, Alexander J, Margherio R, Schachat AP, Fine SL, Stevens TS, Bressler SB. Macular scatter ("grid") laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration: Results of a randomized pilot trial. *Arch Ophthalmol* 1996;114:1456-1464.
75. Levin L, Bressler NM. The case report: when small is beautiful. *Arch Ophthalmol* 1996;114:1413.
76. Enger C, Jabs DA, Dunn JP, Forman MS, Bressler NM, Margolick JB, Charache P, and the CRVR Research Group. Viral resistance and cytomegalovirus retinitis: design and methods of a prospective study. *Ophthalmic Epidemiol* 1997;4:41-48.
77. Stevens TS, Bressler NM, Maguire MG, Bressler SB, Fine SL, Alexander J, Phillips DA, Margherio RR, Murphy PL, Schachat AP. Occult choroidal neovascularization in age-related macular degeneration: A natural history of morphologic changes. *Arch Ophthalmol* 1997;115:345-350.
78. Macular Photocoagulation Study Group (prepared by Maguire MG, Bressler SB, Bressler NM, Marsh MJ, Alexander J, Phillips DA, et al). Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol* 1997;115:741-747.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

79. Pharmacological Therapy for Macular Degeneration Study Group (prepared by Guyer DR, Adamis AP, Yannuzzi LA, Gragoudas ES, Coscas GJ, Brancato R, Bird AC, Soubrane G, Miller J, Bressler NM, Slakter JS, DeRosa J). Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-782.
80. Bressler NM. Submacular surgery: New information; more questions. *Arch Ophthalmol* 1997;115:1071-1072.
81. Sunness JS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS, Haselwood D. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity, *Ophthalmology* 1997;104:1677-1691.
82. Sunness JS, Rubin GS, Appelgate CA, Haselwood D, Marsh MJ, Bressler NM. Visual function and reading rate in eyes with age-related geographic atrophy of the macula and good visual acuity. *Arch Ophthalmol* 1997;104:1677-1691.
83. Loewenstein A, Sunness JS, Bressler NM, Marsh MJ, de Juan E Jr. Scanning laser ophthalmoscope fundus perimetry after surgery for choroidal neovascularization, *Am J Ophthalmol* 1998;125:657-65.
84. deJuan E Jr, Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans. *Am J Ophthalmol* 1998;125:635-646.
85. Schmidt-Erfurth U, Miller JW, Sickenberg M, Bunse A, Laqua H, Gragoudas E, Zografos L, Birngruber R, van den Bergh H, Strong A, Manjuris U, Fsadni M, Lane AM, Piguet B, Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples. *Graefe's Arch Clin Exp Ophthalmol* 1998;236:365-374.
86. Bressler NM. Evaluating new imaging techniques in retina. *Arch Ophthalmol* 1998;116: 521-522.
87. Jabs DA, Enger C, Dunn JP, Forman M, Bressler NM for the CMV Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance. *J Infect Dis* 1998;177:770-773.
88. Rosberger DF, Schachat AP, Bressler SB, Bressler NM. Availability of color fundus photographs from previous visit affects practice patterns for patients with diabetes mellitus. *Arch Ophthalmol* 1998;116:1607-1610.
89. Bressler NM. Reviewers, authors, editors: balance of power. *Arch Ophthalmol* 1999;117:524-526.
90. Cheeseman EW Jr, Bressler NM, Hunter DG. Familial exudative vitreoretinopathy associated with monocular axial myopia. *Retina* 1999;19:257-259.
91. Raja SC, Jabs DA, Dunn JP, Fekrat S, Machan CH, Marsh MJ, Bressler NM. Pars planitis: clinical features and class II HLA associations. *Ophthalmology* 1999;106:594-599.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

92. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate C. Measuring geographic atrophy in advanced age-related macular degeneration. *Invest Ophthalmol Vis Sci* 1999;40:1761-1769.
93. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins BS, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. *Ophthalmology* 1999;106:910-919.
94. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. *Ophthalmology* 1999;106:1656-1659.
95. Bressler NM. In Reply to Letter to the Editor by Freeman, Bartsch, Mueller, and Banker. *Arch Ophthalmol* 1999;117:847.
96. Friedman DS, Katz J, Bressler NM, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. *Ophthalmology* 1999;106:1049-1055.
97. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian YS, Hawkins BS, Barron Y, Bergman A. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. *Ophthalmology* 1999;106:1768-1779.
98. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournas CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas E. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase I and II study. *Arch Ophthalmol* 1999;117:1161-1173.
99. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (corresponding author: Bressler NM). Verteporfin (Visudyne™) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials – TAP report no. 1. *Arch Ophthalmol* 1999;117:1329-1345.
100. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): Natural history study and clinical trial – design implications. AREDS report no. 1. *Control Clin Trials* 1999;20:573-600.
101. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas E, Zografos L, Piguet B, Pournas CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Fsadni M, Bressler NM. Photodynamic therapy of choroidal neovascularization due to age-related macular degeneration with verteporfin: Results of retreatments in a phase I and II study. *Arch Ophthalmol* 1999;117:1177-1187.
102. Bressler NM, Bressler SB. Photodynamic therapy with verteporfin (Visudyne™): Impact on ophthalmology and visual sciences. *Invest Ophthalmol Vis Sci* 2000;41:624-628.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

103. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): A clinical trial of Zinc and Antioxidants. AREDS Report No. 2. *Journal of Nutrition* 2000;130:1516S-1519S.
104. Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournas CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas E, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Fsadni M, Bressler NM. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. *Arch Ophthalmol* 2000;118:327-336.
105. Bressler SB, Bressler NM. Commentary: Retinopathy in patients with type I diabetes four years after intensive therapy. *Arch Ophthalmol* 2000;118:984-985.
106. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: A case-controlled study in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 3. *Ophthalmology* 2000;107:2233-2239.
107. Orr PR, Cramer LD, Hawkins BS, Bressler NM. Manifest refraction versus autorefraction for patients with subfoveal choroidal neovascularization. *Invest Ophthalmol Vis Sci* 2000;42:447-452.
108. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration I. Ophthalmic outcomes, SST Pilot Study Report No. 1. *Am J Ophthalmol* 2000;130:387-407.
109. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration II. Quality of life outcomes, SST Pilot Study Report No. 2. *Am J Ophthalmol* 2000;130:408-418.
110. Bressler NM. Age-related macular degeneration. New hope for a common problem comes from photodynamic therapy. *BMJ* 2000;321:1425-1427
111. Dubovy SR, Hairston RJ, Schatz H, Schachat AP, Bressler NM, Finkelstein D, Green WR. Adult-onset foveomacular pigment epithelial dystrophy. Clinicopathologic correlation of three cases. *Retina* 2000;20:638-49.
112. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularization in age-related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy. *Br J Ophthalmol* 2001;85:483-495
113. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two year results of 2 randomized clinical trials – TAP report no. 2. *Arch Ophthalmol* 2001;119:198-207.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

114. Verteporfin In Photodynamic Therapy (VIP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One year results of a randomized clinical trial – VIP report no. 1. *Ophthalmology* 2001;108:841-852.
115. Bressler NM, Hawkins BS, Sternberg P Jr, McDonald HR. Are the Submacular Surgery Trials (SST) still relevant in an era of photodynamic therapy? *Ophthalmology* 2001;108:435-436.
116. Verteporfin in Photodynamic Therapy (VIP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two year results of a randomized clinical trial including lesions with occult but no classic neovascularization – VIP report no. 2. *Am J Ophthalmol* 2001;131:541-560.
117. Bressler SB, Bressler NM. Randomized clinical trials in ophthalmology in 2001: Twenty-fifth anniversary of the first publication from the Diabetic Retinopathy Study. *Am J Ophthalmol* 2001;131:503-504.
118. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. *Am J Ophthalmol* 2001;131:167-175.
119. Bressler NM. The impact of photodynamic therapy on the management of age-related macular degeneration. *Saudi Journal of Ophthalmology* 2001;15:1-4.
120. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract: A case-control study in the Age-Related Eye Disease Study: AREDS report no. 5. *Ophthalmology* 2001;108:1400-1408.
121. Ladd BS, Solomon SD, Bressler NM, Bressler SB. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy. *Am J Ophthalmol* 2001;132:659-667.
122. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: AREDS report no. 6. *Arch Ophthalmol* 2001;119:1417-1436.
123. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol* 2001;119:1417-1436.
124. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Arch Ophthalmol* 2001;119:1439-1452.
125. Fujii GY, de Juan E Jr, Bressler NM. Vitrectomy surgery for impending macular hole based on optical coherence Tomography. *Retina* 2001;21:389-392.
126. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. *J Am Board Fam Pract* 2002;15:142-152.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

127. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne[®]) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2002;22:6-18.
128. Bressler NM. In response to: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2. Letter to Editor. *Am J Ophthalmol* 2002;133:168-169.
129. Ng EWM, Bressler NM, Boyer DS, de Juan E. Iatrogenic choroidal neovascularization occurring in patients undergoing macular translocation surgery. *Retina* 2002;22:711-718.
130. The Age-Related Eye Disease Study Research Group. The Effect of Five-Year Zinc Supplementation on Serum Zinc, Serum Cholesterol and Hematocrit in Persons Randomly Assigned to Treatment Group in the Age-Related Eye Disease Study: AREDS report no. 7. *Journal of Nutrition* 2002;132:697-702.
131. Rubin GS, Bressler NM, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity; results from the Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) Investigation: TAP Report No. 4. *Retina* 2002;22:536-544.
132. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials –TAP Report No. 5 (Corresponding author: Bressler NM). *Arch Ophthalmol* 2002;120:1307-1314.
133. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes – TAP Report No. 3. (Corresponding author: Bressler NM). *Arch Ophthalmol* 2002;120:1443-1454.
134. Bressler NM for the Verteporfin in Photodynamic therapy (VIP) Study Group: Author reply to letter to editor. *Ophthalmology* 2002;109:1043-1044.
135. Bressler NM. Prognosis for placebo-treated eyes in VIP Report 2: author reply. *Am J Ophthalmol* 2002;133:295-296.
136. Bressler NM, Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: author reply. *Am J Ophthalmol* 2002;133:857-859.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

137. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: One-year results of an uncontrolled, prospective case series. *Ophthalmology* 2002;109:1499-1505.
138. Yang Y, Vitale S, Ding Y, O'Connell, SR, Alexander J, Bressler NM, Schachat AP, Zeimer R. A comparison of quantitative mapping and stereoscopic fundus photography grading thickness in diabetic eyes with macular edema. *Ophthalmic Surg Lasers Imaging* 2002; 34:1.
139. Bressler NM. Commentary: Retinal arteriolar narrowing and risk of coronary heart disease. *Arch Ophthalmol* 2003;121:113-114.
140. Margalit E, Bressler NM. Retinal pigment epithelium tumor-like lesion arising from area of laser photocoagulation. *Arch Ophthalmol* 2003;121:130-131.
141. Bressler NM, Apte RS. Foveal congenital hypertrophy of the retinal pigment epithelium in the setting of geographic atrophy from age-related macular degeneration. *Am J Ophthalmol* 2003;135:120-121.
142. Sawa M, Masahito O, Gomi F, Kusaka S, Tano Y, Bressler NM. Apparent disappearance of choroidal neovascularization after initial photodynamic therapy with verteporfin. *Am J Ophthalmol* 2003;120:1588-1590.
143. Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization — SST report No.1. *Arch Ophthalmol* 2003;121:531-539. [Correction *Arch Ophthalmol* 2003;121:1513.]
144. Verteporfin In Photodynamic Therapy Study Group (Corresponding author: Bressler NM). Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: Two-year results of a randomized clinical trial — VIP report no. 3. *Ophthalmology* 2003;110: 667-673.
145. Improvement After Verteporfin Therapy Writing Committee for the TAP Study Group. Improvement after verteporfin therapy. *Arch Ophthalmol* 2003;121:415-416.
146. Japanese Age-related Macular Degeneration Trial (JAT) Study Group. Japanese Age-related Macular Degeneration Trial (JAT): One-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Am J Ophthalmol* 2003;136:1049-1061.
147. Mimouni KF, Bressler SB, Bressler NM. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children. *Am J Ophthalmol* 2003;135:900-902.
148. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change from baseline with and without verteporfin therapy in choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 (Corresponding author: Bressler NM). *Am J Ophthalmol* 2003;136:407-418.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

149. Clemons TE, Chew EY, Bressler SB, McBee W, for the AREDS Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS report no. 10. *Arch Ophthalmol* 2003;121:211-217
150. Diloreto DA, Bressler NM, Bressler SB, Schachat AP. Use of best and final visual acuity outcomes in ophthalmologic research. *Arch Ophthalmol* 2003;121:1586-1590.
151. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment – TAP and VIP Report no. 2. *Arch Ophthalmol* 2003;121:1253-1268.
152. The Age-Related Eye Disease Study Research Group. Potential public health impact of AREDS results: AREDS Report No. 11. *Arch Ophthalmol* 2003;121:1621-1624.
153. Hubbard LD, Ricks MO, Martin BK, Bressler, Kempen JH, Dunn JP, Jabs DA. Comparability of two fundus photographs reading centers in grading CMV retinitis progression. *Am J Ophthalmol* 2004;137:426-434.
154. Subramanian PS, Bressler NM, Miller NR. Radiation retinopathy after fractionated stereotactic radiotherapy for optic nerve sheath meningioma. *Ophthalmology* 2004;111:565-567.
155. Do DV, Bressler, NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. *Am J Ophthalmol* 2004;137:558-560.
156. Submacular Surgery Trials Pilot Research Group. Responsiveness of the SF-36 health survey to changes in visual acuity amount patients with subfoveal choroidal neovascularization. *Am J Ophthalmol* 2004;137:373-375.
157. Miskala PH, Bressler NB, Meinert CL. Is adjustment of NEI-VFQ scores for general health necessary in randomized trials? *Am J Ophthalmol* 2004;137:961-963.
158. Submacular Surgery Trials Research Group. Clinical trial performance of community-based compared with university-based practices: Lessons from the Submacular Surgery Trials, SST Report no. 2. *Arch Ophthalmol* 2004;122:857-863.
159. Treatment of Age-related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Trial Study Groups. Acute severe visual acuity decrease following photodynamic therapy with verteporfin: Case reports from randomized clinical trials – TAP and VIP Report no. 3. *Am J Ophthalmol* 2004;137:683-696.
160. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation: Outcomes potentially relevant to management – TAP Report no. 6. *Arch Ophthalmol* 2004;122:325-329.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

161. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Meta-analysis of two-year safety results in three randomized clinical trials – TAP and VIP Report no. 4. *Retina* 2004;24:1-12.
162. Diloreto DA, Bressler NM, Goldberg MF. Choroidal neovascularization after central retinal vein occlusion in a 47-year-old man. *Arch Ophthalmol* 2004;122:1398-1401.
163. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: Contact lens biomicroscopy compared with optical coherence tomography. *Arch Ophthalmol* 2004;122:330-335.
164. Miskala PH, Bressler NM, Meinert CI. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. *Arch Ophthalmol* 2004;122:758-766.
165. Bressler NM, Liesegang T, Schachat AP, Albert DM. Advantages and potential dangers of presentation before publication: Third in a series on editorship. *Arch Ophthalmol* 2004;122:1045-1048 .
166. Rosenfeld PJ, MD, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M, Rosa RH, Sternberg P, Aaberg TM, Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: Uncontrolled, open-label 2-year study. *Ophthalmology* 2004;111:1725-1733.
167. Blair MP, Apte RS, Miskala PH, Bressler SB, Goldberg MF, Schachat AP, Bressler NM. A retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. *Retina* 2004;24:501-506.
168. Submacular Surgery Trials Research Group. Health and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at time of enrollment in randomized trials of submacular surgery: SST Report no. 4. *Am J Ophthalmol* 2004;138:91-108.
169. The Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): Rationale, design, methodology. *Clinical Trials* 2004;1:91-107.
170. Bressler NM, Age-related macular degeneration is the leading cause of blindness. *JAMA* 2004; 291:1900-1901.
171. Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. AREDS Report no. 12. *Neurology* 2004;63:1705-1707.
172. VAM Study Writing Committee (Corresponding author Bressler NM). Verteporfin therapy in age-related macular degeneration (VAM): An open-label multicenter photodynamic therapy study of 4,435 patients. *Retina* 2004;24:512-520.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

173. The Age-Related Eye Disease Study Research Group. Association of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study. AREDS Report no. 13. *Arch Ophthalmol* 2004;122:716-726.
174. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. I. Ophthalmic findings from a randomized clinical trial: SST Group H Trial. SST Report no. 9. *Arch Ophthalmol* 2004;122:1597-1611.
175. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic – II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial. SST Report no. 10. *Arch Ophthalmol* 2004;122:1616–1628.
176. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings. SST Group N Trial. SST Report no. 11. *Ophthalmology* 2004;111:1967-1980.
177. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality of life findings. SST Group N Trial. SST Report no. 12. *Ophthalmology* 2004; 111:1981-1992.
178. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions in age-related macular degeneration: Ophthalmic findings. SST Group B Trial. SST Report no. 13. *Ophthalmology* 2004;111:1993-2006.
179. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions in age-related macular degeneration: Quality-of-life findings. SST Report 14. *Ophthalmology* 2004;111:2007-2014.
180. Submacular Surgery Trials Research Group. Patients’ perceptions of the value of current vision: Assessment of preference values among patients with subfoveal choroidal neovascularization – the Submacular Surgery Trials Vision Preference Value Scale: SST Report no. 6. *Arch Ophthalmol* 2004;122:1856-1867.
181. The Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
182. Sadda SR, Pieramici DJ, Marsh MJ, Bressler NM, Bressler SB, for the Submacular Surgery Trials Pilot Study Investigators. Changes in lesion size after Submacular Surgery for subfoveal choroidal neovascularization in the Submacular Surgery Trials Pilot Study. *Retina* 2004;24:888-899.
183. VIP Report No. 5 Writing Committee. Letter to Editor. Verteporfin in Photodynamic Therapy: Report no. 5. *Ophthalmology* 2004;111:2144.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

184. Responsiveness of the NEI-VFQ to progression to advanced AMD, vision loss, lens opacity, and cataract surgery. AREDS Report No. 14. *Arch Ophthalmol* 2004;123:1201-1206.
185. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 19. *Ophthalmology* 2005;112:533-539.
186. Schein OD, Bressler NM, Price P. Photodynamic therapy with verteporfin: Observations on the introduction of a new treatment into clinical practice. *Arch Ophthalmol* 2005;123:58-63.
187. Submacular Surgery Trials Research Group. Health and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at time of enrollment in a randomized trial of submacular surgery. SST Report no. 5. *Arch Ophthalmol* 2005;123:78-88.
188. Submacular Surgery Trials Research Group. Effect of order of administration of health-related quality of life interview instruments on responses: SST Report no. 3. 2005; *Qual Life Res* 2005;14:493-500.
189. Submacular Surgery Trials (SST) Research Group. Histopathological and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: SST Report no. 7. *Arch Ophthalmol* 2005;123:914-921.
190. Submacular Surgery Trials (SST) Research Group. Guidelines for interpreting retinal photographs in the Submacular Surgery Trials (SST): SST Report No. 8. *Retina* 2005;25:253-268.
191. Verteporfin Roundtable 2003 Participants. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2005; 25:119-134.
192. Bressler NM. Cystoid macular edema from niacin typically is not accompanied by fluorescein leakage on angiography (Letter to Editor). *Am J Ophthalmol* 2005;139:951.
193. Orr PR, Marsh MJ, Hawkins BS, Hawse PL, Bressler NM. Evaluation of the traveling vision examiner program of the Submacular Surgery Trials Pilot Study. *Ophthalmic Epidemiology* 2005;12:47-57.
194. Visudyne® In Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-Year Results of a Randomized Clinical Trial. *Arch Ophthalmol* 2005;123:448-457.
195. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal Neovascularization in age-related macular degeneration: Four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. *Arch Ophthalmol* 2005;123:1283 -1285
196. Bressler SB, Bressler NM. Dick Green Tribute. *Retina* 2005;25:S1-S28.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

197. The Macugen Diabetic Retinopathy Study Group. A Phase II randomized, double-masked, trial of pegaptanib, an anti-vascular endothelial growth factor Aptamer, for diabetic macular edema. *Ophthalmology* 2005;112:1747-1757.
198. Preferential Hyperacuity Perimeter (PHP) Research Group. Preferential Hyperacuity Perimeter (PreView PHP™) for detecting choroidal neovascularization study. *Ophthalmol* 2005;112:1758-1765.
199. Bressler NM: Retinal anastomosis to choroidal neovascularization: A bum rap for a difficult disease? *Arch Ophthalmol* 2005;123:1741-1743.
200. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. *Ophthalmology* 2005;112:2088–2094
- 201 The Age-Related Eye Disease Study Research Group. The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. *Arch Ophthalmol*. 2005;123:1484-1498.
202. The Age-Related Eye Disease Study Research Group: A simplified severity scale for age-related macular degeneration. AREDS Report No. 18. *Arch Ophthalmol* 2005; 123:1570-1574.
203. Kim SJ, Equi R, Bressler NM: Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. *Ophthalmology* 2007; 114:881-889..
204. Submacular Surgery Trials (SST) Research Group. Comparison of 2-dimensional reconstructions of surgically-excised choroidal neovascularization with fluorescein angiographic features: SST Report No. 15. *Ophthalmology* 2006;113:267–279
205. Verteporfin In Photodynamic Therapy (VIP) Study Groups. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: Clinically relevant natural history information in larger lesions with good vision from the verteporfin in photodynamic therapy (VIP) Trial - VIP Report No. 4. *Arch Ophthalmol* 2006;124:660-664.
206. The Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization following pegaptanib (macugen) therapy in diabetic individuals. *Ophthalmology*; 2006;113:23–28
207. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of 2 randomized clinical trials with an open-label extension—TAP Report No. 8.
208. The Age-Related Eye Disease Study Research Group. Cognitive impairment in the age-related eye disease study. AREDS Report No. 16. *Arch Ophthalmol* 2006; 124:537-543.
209. The Age-Related Eye Disease Study Research Group: centrum use and progression of age-related cataract in the age-related eye disease study. AREDS report no. 21. *AAO* 2006; 113: 1264-1270.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

210. Do DV, Nguyen QD, Bressler NM, Schachat AP, Solomon SD, Melia M, Bressler SB: Hemoglobin A1C awareness among patients receiving eye care at a tertiary ophthalmic center. *AM J Ophthalmol* 2006; 141: 951-953.

211 Submacular Surgery Trials (SST) Research Group. Clinicopathologic studies of eyes obtained post-mortem from four patients enrolled in the Submacular Surgery Trials: SST Report No. 16. *Am J Ophthalmol* 2006;141:93–104.

212 [-----], *in press*.

213 [-----]. *in press*

214. [-----], *in press*.

215. Diabetic Retinopathy Clinical Research Network. A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study. *Ophthalmology* 2007; 114:1190-1196.

216. [-----], *in press*.

217. Diabetic Retinopathy Clinical Research Network. Comparison of Modified-ETDRS and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular Edema, *Arch Ophthalmology* 2007; 125:469-480.

218. [-----], *in press*.

219. [-----]. *in press*.

220. [-----]-Submitted
for Publication.

221. Sunness JS, Margalit E, Srikumaran DG, Applegate CA, Tian Y, Perry D, Hawkins BS, Bressler NM: The long-term natural history of geographic atrophy from age-related macular degeneration: Enlargement of atrophy and implications for interventional clinical trials. *Ophthalmology* 2007; 114: 271-277.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

222. Aged-Related Eye Disease Study Research Group. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study. AREDS Report No. 20. *Arch Ophthalmology* 2007; 125:671-679.

223. [-----]
-----], in
press.

FULL TEXTBOOKS

Bressler NM, Brown GC, Flynn HW, Marmor MF, Anderson LS, Grand MG. American Academy of Ophthalmology's Basic Clinical Skills Course Section 12: Retina and Vitreous, 1996-1997, 1996.

BOOK CHAPTERS

1. Bressler NM, Bressler SB, Berson FG: Ophthalmic agents. In Manual of Drug Therapy. Eds. Steinberg DA, Scheinberg LC. New York: Raven Press, 1985.
2. Bressler SB, Bressler NM, Murphy RP: Argon laser treatment: randomized clinical trials--short and long term results. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
3. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
4. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Laser Photocoagulation of Retinal Disease. Eds Gitter KA, Schatz H, Yannuzzi LA, McDonald HR. San Francisco: Pacific Medical Press, 1988.
5. Bressler NM, Bressler SB: Laser treatment in macular degeneration and histoplasmosis. In Ophthalmology Clinics of North America: Practical Laser Surgery and Its New Frontiers. Ed March WF. Philadelphia: WB Saunders Co, 1989.
6. Boldt C, Bressler NM, Fine SL, Bressler SB: Age-related macular degeneration. *Current Opinion in Ophthalmol* 1:277-257, 1990.
7. Bressler SB, Bressler NM: Traumatic maculopathy. In Ocular Trauma. Eds, Hersh P, Shingleton B, Topping T, 1991.
8. Bressler NM, Bressler SB, Fine SL: Angiographic interpretation of classic and occult choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St. Louis: Mosby Year Book, 1992.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

9. Bressler NM: Macular degeneration and related disorders. In Practical Atlas of Retinal Disease and Therapy. Ed. Freeman WR. New York: Raven Press, 1992.
10. Bressler SB, Gragoudas ES, Bressler NM: Age related macular degeneration, Part 1: Drusen and Geographic Atrophy. In Principles and Practice of Ophthalmology. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1993.
11. Bressler NM, Gragoudas ES, Bressler SB: Age related macular degeneration, Part 2: RPE Detachment and Subretinal neovascularization. In Principles and Practice of Ophthalmology. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1993.
12. Bressler SB, Bressler NM, Fine SL: Photocoagulation of choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St Louis: Mosby Year Book, 1994.
13. Bressler NM: Laser management of choroidal neovascularization. Focal Points Module, American Academy of Ophthalmology, 1993.
14. Custis PH, Bressler SB, Bressler NM: Laser management of subfoveal choroidal neovascularization, Current Opinion in Ophthalmology, 4:III:7-18, 1993.
15. Neely KA, Bressler NM, Bressler SB: Epidemiology, clinical characteristics, and natural history of age-related macular degeneration. In Ophthalmology Clinics of North America: Macular Diseases. Eds., Grossniklaus HE, Kincaid MC. WB Saunders Co, 1993.
16. Dyer DS, Bressler SB, Bressler NM: The role of laser wavelength in the treatment of vitreoretinal diseases. Current Science, 5;III:35-43, 1994.
17. Zimmer-Galler I, Bressler NM, Bressler SB: Treatment of choroidal neovascularization: Updated Information from the Macular Photocoagulation Study Group reports. International Ophthalmic Clinics, Little, Brown and Company, 35 (4):37-57,1995.
18. Bressler NM: Subretinal neovascular membrane. Master Techniques in Ophthalmic Surgery. Ed., Roy FH. Williams and Wilkins, 1995.
19. MacCumber MW, Connor TB, Bressler NM: Management of ocular injuries. J.P. Lippincott, Co., 1997.
20. Bressler NM: Macular degeneration and related disorders. In Practical Atlas of Retinal Disease and Therapy 2nd edition. Ed. Freeman WR. New York: Raven Press, 1997.
21. [-----
----] (in press) [--].
22. Rosberger DF, Bressler NM, Bressler SB: Ophthalmic Surgery: Photocoagulation. Rob & Smith's Operative Surgery, Eds., Carter DC, Russell RCG, Pitt HA, Dudley H, Lee G, Remes P, Stockman L, Ramage D. Chapman & Hall, 1998.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

23. Loewenstein A, Bressler NM: Macular Photocoagulation Study. *Retina, Vitreous, Macula: A Comprehensive Text*, Eds., Guyer DR, Yannuzzi LA, Chang S, Shields J, Green WR. Saunders Publishing Company, Philadelphia, PA, 1998.
24. Bressler NM, Edwards M: Age-related macular degeneration. In *Ophthalmology*, section 8: Retinal and Vitreous. Ed. Duker J. Mosby-Wolfe Publishing, London, 1998.
25. Loewenstein A, Bressler NM, Bressler SB. Epidemiology of RPE disease. In *Retinal Pigment Epithelium: Current Aspects of Function and Disease*. Eds. Marmor MF, Wolfensberger TJ. New York: Oxford University Press, 1999.
26. O'Connell SR, Bressler NM: Age-related macular degeneration. In *The Essentials of VitreoRetinal Disease*, 1st edition. Ed. Brown GC, Flynn HW, Regillo CD. New York, Thieme Medical Publishing, 1998.
27. Bressler SB, Gragoudas ES, Bressler NM: Age-related macular degeneration, Part 1: Drusen and Geographic Atrophy. In *Principles and Practice of Ophthalmology*, 2nd Edition. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1999.
28. Bressler NM, Gragoudas ES, Bressler SB: Age-related macular degeneration, Part 2: RPE Detachment and Subretinal neovascularization. In *Principles and Practice of Ophthalmology*, 2nd Edition. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1999.
29. Bressler NM, Bressler SB, Fine SL: Neovascular (exudative) age-related macular degeneration. In *Medical and Surgical Retina: Advances, Controversies and Management (Third Edition)*. Eds Ryan S, Schachat AP. St Louis: Mosby Year Book, 2000.
30. Weisz JM, Bressler NM, Bressler SB: Choroidal neovascularization: Laser treatment. In *Macular Surgery*. Eds Quiroz-Mercado H, Liggett P, Alfaro V, de Juan E, Tano Y. Lippincott, Williams & Wilkins, July 2000.
31. [-----]
-----] In press, [---]

FEDERALLY-SUPPORTED (National Institutes of Health) RESEARCH GRANTS

CURRENTLY ACTIVE NIH SUPPORT:

1. Submacular Surgery Trials: Study Chairman's Office Grant
NIH Grant - 1 U10 EY11547-01
Principal Investigator (*and Study Chairman*) – Up to 20% effort and support
Project Period: 9/30/96 - 4/30/05

Purpose: Multicenter randomized clinical trials designed to determine if submacular surgery can reduce the risk of visual loss in patients with choroidal neovascularization due to age-related macular

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

degeneration (the leading cause of severe visual loss in people over 65 in the United States and Western World), the ocular histoplasmosis syndrome or idiopathic causes.

2. Diabetic Retinopathy Clinical Research Network: Network Chair's Office.

NIH Grant

Network Chair Elect (2005); Network Chair 2006 – 20% effort

Project Period: 01/01/05 – 12/31/10

Purpose: To serve as Chair Elect and then as Chair of a network of clinical studies on diabetic retinopathy within a network of clinical centers, serving as Principal Investigator elect and then Principal Investigator of the Network Chair's Office.

3. Submacular Surgery Trials (SST) Pathology Center

NIH Grant -1 U10 EY 12662-01

Consultant – 2% effort

Project Period: 8/99 - 7/05

Purpose: To evaluate the clinicopathologic correlations of choroidal neovascularization structure and biochemistry from patients in comparison to their pre-surgery vision data, color fundus photographs, fluorescein angiograms, and visual outcomes. Additionally, post-mortem examination of eyes from patients enrolled in the SST will enable correlation of tissue changes in both operated and unoperated eyes with clinical data.

4. Age-Related Eye Disease Study

NIH Grant - N01-EY-0-2111

Co-investigator - 2% effort (0% financial support)

Project Period: 07/01/90 - 06/30/05

Purpose: A study of the development and progression of cataracts and macular degeneration in people ages 60 to 75 and influence of nutritional supplements on these conditions.

COMPLETED NIH SUPPORT:

1. Age-Related Geographic Atrophy

NIH Grant -2 R01 EY0D08522-06A1

Co-Principal Investigator - 5% effort and support

Project Period: 9/30/98-9/29/00

Purpose: To determine natural history of patients with geographic atrophy from age-related macular degeneration to determine risk factors for visual loss and potential patient groups for interventional trials.

2. Application of Non Invasive Retinal Thickness

NIH Grant - R01 EY06976-08A1

Co-Principal Investigator - 5% effort and support

Project Period: 7/1/94-7/1/99

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Purpose: Study the relationship between retinal thickness, measured by a novel optical technique, and the natural history and effect of laser treatment on diabetic macular edema.

3. Effect of Cataract & Age-Related Maculopathy on Vision

NIH Grant - R01 EY06380-09
Co-Investigator - 4% effort and support
Project Period: 1/1/95-3/31/99

Purpose: Develop a set of tools that will allow one to determine the potential benefits of cataract surgery in patients with age-related macular degeneration.

4. CMV Retinitis and Viral Drug Resistance

NIH Grant - 1R01 EY05952
Co-Investigator - 9% effort and support
Project Period: 7/1/93-6/30/98

Purpose: Epidemiologic study to determine the incidence and prevalence of resistant cytomegalovirus (CMV) in patients treated for CMV retinitis, as well as risk factors for its development.

5. Geographic Atrophy Study

NIH Grant - EY08552-01
Co-Investigator - 4% effort and support
Project Period: 03/01/92-02/28/97

Purpose: 5-Year natural history study of progressive loss of central vision due to geographic atrophy.

6. Submacular Surgery Trials Planning Grant

NIH Grant - R21 EY10823-01
Principal Investigator (*Study Chairman*) - 10% effort (0% financial support)
Project Period: 1/1/95 - 3/31/96

Purpose: To obtain support for activities required to plan and organize a multicenter study evaluating the role of submacular surgery in age-related macular degeneration and the ocular histoplasmosis syndrome.

7. Macular Photocoagulation Study Reading Center

NIH Grant - EY05958-09
Principal Investigator - 20% effort and support
Project Period: 9/30/85 - 3/31/95

Purpose: Evaluate fundus photographs and angiograms of all participants in the Macular Photocoagulation Study; collaborate with Coordinating Center.

8. Macular Photocoagulation Study:

NIH Grant EY02556-12
Principal Investigator - 5% effort and support
Project Period: 1/1/79 - 12/31/93

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Purpose: Direct the clinical center at Wilmer randomizing patients to laser treatment or no treatment in the Macular Photocoagulation Study.

9. Follow-up Study of Eye Disease in a Cohort of Chesapeake Bay Watermen

NIH Grant EY08776-01

Co-investigator - 10% effort and support

Project Period: 07/01/90 - 12/30/92

Purpose: Longitudinal evaluation of cataract and macular degeneration in a population-based study.

INDUSTRY/FOUNDATION SUPPORTED RESEARCH GRANTS

CURRENTLY ACTIVE INDUSTRY/FOUNDATION SUPPORT:

1. Natural History of Subclinical Diabetic Macular Edema

Sponsor: [-----]

Principal Investigator – Up to [-] % effort and support

Project Period: 8/1/04 – 07/30/07

Purpose: To evaluate the natural history of diabetic macular edema detected on optical coherence tomography but not clinical examination compared with no edema on either optical coherence tomography or clinical examination among individuals with diabetic retinopathy.

2. Clinical Development and Research Support Office of Johns Hopkins University's Department of Ophthalmology (Wilmer Eye Institute)

Sponsor: [-----]

Principal Investigator – Up to [-] % effort and support

Project period: 4/1/04 – 6/30/06

Purpose: To assist in the planning, design, and implementation of clinical trials, with specific reference to retinal diseases.

3. Johns Hopkins University School of Medicine Institutional Consulting Agreements

Sponsors: [-----]

Principal Investigator – Up to [--] % effort and support

Project period: 07/01/03 – 6/30/06

Purpose: To provide consulting on behalf of the Johns Hopkins University to various industries regarding the planning, design, and implementation of clinical trials, with specific reference to retinal diseases.

COMPLETED INDUSTRY/FOUNDATION SUPPORT:

1. Phase II Study of the Effect of Visudyne Therapy with Reduced Light Doses/Fluence Rates on the Fluorescein Outcomes in Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (RF)

Co-investigator, [-----] % effort and support

Project Period: 3/1/00 - 2/28/01

Purpose: To serve as Co-investigator, [-----] for the RF study which is evaluating, primarily, if fluorescein leakage from the classic portion of the CNV lesion can be reduced, and

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

secondarily, if fluorescein leakage from the occult portion of the lesion and visual acuity can be improved, after Visudyne therapy using reduced light doses achieved by reduced light fluence rates compared with Visudyne therapy using the standard light dose and fluence rate.

2. [-----].

Co-investigator, [-----]% effort and support
Project Period: 11/1/00 - 2/28/01

Purpose: To serve as Co-investigator, [-----] for the VIO study which is a randomized, placebo-controlled, double-masked, multicenter, phase III, study of the effect of Visudyne therapy in occult with no classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.

3. Verteporfin In Photodynamic Therapy (VIP) (Phase 3b Investigation) – [-----]

Chairman, Study Advisory Group
Co-Investigator, [-----]% effort and support
Project Period: 1/1/98 - 12/31/00

Purpose: To serve in a capacity as Study Chairman to the Study Advisory Group and 28 participating clinical centers whose purpose is to scientifically direct a randomized, controlled, multicenter clinical trial to determine the role of photodynamic therapy with liposomal benzoporphyrin derivative monoacid (verteporfin) for treating early choroidal neovascularization due to macular degeneration or pathologic myopia. Also, to assist in activities of the [-----] for this trial and direct protocol monitoring of vision examiners.

4. [-----]

Principal Investigator – [-----]% effort and support
Project Period: 10/98 - 9/00

Purpose: To serve as Principal Investigator of a clinical center at Johns Hopkins University to assess the safety of AG3340 in patients with subfoveal CNV associated with AMD, to determine the dose and regimen of AG3340 to be used in a phase III trial, to assess the effect of AG3340 on visual function in patients with subfoveal CNV associated with AMD, and to study the effect of AG3340 on morphologic changes of subfoveal choroidal neovascular lesions over time.

5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (Phase 3 Investigation) – [-----]

Chairman, Study Advisory Group
Co-Investigator, [-----]% effort and support
Project Period: 9/1/96 - 8/31/00

Purpose: To serve in a capacity as Study Chairman to the Study Advisory Group and 22 participating clinical centers whose purpose is to scientifically direct a randomized, controlled, multicenter clinical trial to determine the role of photodynamic therapy with liposomal benzoporphyrin derivative monoacid (verteporfin) for treating choroidal neovascularization due to age-related macular degeneration. Also, to assist in activities of [-----] for this trial and direct protocol monitoring of vision examiners.

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

6. Photodynamic Therapy Trial for Neovascular AMD: Phase I/II [-----].
Chairman, Scientific Advisory Group
[-----]% support
Project Period: 10/1/94 - 12/31/96

Purpose: An open, multicenter, non-controlled phase I/II study of the treatment of choroidal neovascularization using photodynamic therapy with liposomal benzoporphyrin derivative monoacid (verteporfin)

7. Laser to Drusen to Prevent CNV Trial – [-----]
Principal Investigator - Neil M. Bressler, M.D. – [-]% support
Project Period: 1/1/94-12/31/96
Purpose: Study to determine if laser treatment can prevent the development of choroidal neovascularization in high risk eyes.

8. Research to Prevent Blindness [-----]
Recipient - Neil M. Bressler, M.D.
Project Period: 7/1/95-6/30/96
Purpose: To assist in clinical studies on age-related macular degeneration.

9. Roferon-A in Age-related Macular Degeneration Study – [-----]
Principal Investigator - Neil M. Bressler, M.D. – [-]% support
Project Period: 7/1/93-12/31/95
Purpose: To determine whether Roferon-A can reduce visual loss in patients with subfoveal choroidal neovascularization due to age-related macular degeneration.

10. Laser to Drusen to Prevent CNV Trial – [-----]
Principal Investigator - Neil M. Bressler, M.D. –[--]%
Project Period: 1/1/94-12/31/94
Purpose: Pilot study to determine if patients can be identified, recruited, and treated with no deleterious effects. These results will be used to determine if a larger multi-center trial is feasible to determine if laser treatment can prevent the development of CNV in high risk eyes.

11. [-----]Trial ([-])
Advisor
Co-Investigator, [-----]% effort and support
Project Period: 07/01/99 to 3/31/02
Purpose: To serve in a capacity as Advisor to 4 participating clinical centers in [---] whose purpose is to confirm the efficacy and safety (ocular and systemic) of verteporfin in [-----] patients with subfoveal CNV due to AMD presenting with some classic CNV lesions. Also, to assist in activities of the [-----] for this trial and direct protocol monitoring of vision examiners.

12. Visudyne Early Retreatment (VER) – [-----]
Chairman, Study Advisory Group
Co-Investigator, [-----]% effort and support
Project Period: 11/01/00 - 10/31/04

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Purpose: To serve in a capacity as Study Chairman to the Study Advisory Group and clinical centers whose purpose is to scientifically direct a multicenter, randomized, parallel group, double-masked, controlled phase IIIb, 2-year study comparing the efficacy and safety of Visudyne Therapy with Early Retreatment to Standard Treatment in predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. Also, to assist as Co-investigator in activities of the [-----] for this trial and direct protocol monitoring of vision examiners.

13. Visudyne Therapy in Minimally Classic Subfoveal CNV (VIM) – [-----]
Chairman, Study Advisory Group
Co-Investigator, [-----]% effort and support
Project Period: 11/01/00 - 10/31/04

Purpose: To serve in a capacity as Study Chairman to the Study Advisory Group and clinical centers whose purpose is to scientifically direct a randomized, placebo-controlled, double-masked, multicenter, phase II/III, study of the effect of Visudyne therapy in minimally classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. Also, to assist as Co-investigator in activities of the [-----] for this trial and direct protocol monitoring of vision examiners.

EDITORIAL ROLES

Editorial Boards:

Archives of Ophthalmology
Retina
Advanced Studies in Ophthalmology (Founding Editor-in-Chief)

Completed Editorial Boards

1991-1994 Section Editor (Reviews in Medicine), Survey of Ophthalmology
1995-2000 The Wilmer Retina Update, Editor-in-Chief (*and Founding Editor*)

Ad Hoc Reviewer in Last Few Years:

American Journal of Ophthalmology
British Journal of Ophthalmology
Eye
JAMA
Investigative Ophthalmology and Visual Science
New England Journal of Medicine
Ophthalmology

NATIONAL ADVISORY ROLES

Scientific Advisor: NEI Research for Macular Degeneration: February 1990 - December 1990.

Consultant - American Academy of Ophthalmology Preferred Practice Pattern for Macular Degeneration – 1990 - 1994

Ad Hoc Reviewer - National Eye Institute - Study Sections – 1993 to present

Editor - Basic and Clinical Science Course - Retina Section - American Academy of Ophthalmology - 1994-1998

Scientific Advisory Council: The Macula Foundation, Inc.- 2002 – present

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Scientific Advisor - American Federation of Aging Research - 1992-1997

National Eye Institute (NEI) Special Emphasis Panel Review Committee – member: 1997,1998, 2001, 2003

Ophthalmic Devices Panel of the Medical Devices Advisory Committee for the Center for Devices and Radiologic Health, Food and Drug Administration: 2000 - present

U.S. Pharmacopeia Expert Committee - Member, 2000 – 2005, 2005-2010

Carotene in Age-Related Eye Disease Study (CAREDS) Scientific Advisory Board for National Eye Institute – 2002 - present

SCORE Advisory Group Member – National Eye Institute: 2003 - present

Member, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of National Institutes of Health – 2002

Chair, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of National Institutes of Health – 2003 - present

PROFESSIONAL SOCIETIES AND SERVICE TO PROFESSIONAL SOCIETIES

1981-2005 Association for Research in Vision and Ophthalmology
1995-1998 Program Committee (Chairman of Program Committee in 1998)
1998-2002 Exhibits Committee (Chairman 2002)

1987-2005 American Medical Association

1987-2005 American Academy of Ophthalmology
1994-1997 Editor, Basic and Clinical Science Course: *Retina Section*
1990-2004 Consultant, Preferred Practice Patterns

1990-2005 Macula Society
1996-2002 Member, *Executive Committee*
1996-2002 Chairman, *Program Committee*
1994-1997 Member, *Research Committee*

1993-2005 Retina Society

1997-2004 Society for Clinical Trials
1998-2002 Member, *Development Committee*

1998-2004 Club Jules Gonin

1998-2005 American Society of Retina Specialists
2005 Chair, *Ad hoc* Leadership Committee

2003-2005 American Academy of Ophthalmology
Member, *Committee on Aging*

EDUCATIONAL RESPONSIBILITIES

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

Medical Students:

Year 2:

Pathophysiology Lecture: Posterior segment of the eye (1 time per year)
Clinical Skills Introduction to Ophthalmology Lecture (1 time per year)

Years 3 and 4:

Required Clerkship--3 lectures (5 times per year)
Required Clerkship--Student observer for patients (up to 5 times per year)
Elective Clerkship--1 lecture (up to 6 times per year)
Elective Clerkship--Student observer for patients (up to 6 times per year)
Elective Clerkship--Sporadically, a student will work for 2-3 months on a clinical research project, culminating in a publication to be authored by the student (see for example, article by Sykes SO et al, *Arch Ophthalmol*, December 1994).

Residents:

Direct 2nd year resident rotation in retina.

Supervise 2nd year resident 1 day per week in the management of retinal diseases in patients from the residents clinic as well as from my practice.

Teach approximately 6 lectures per year as part of the residents' didactic morning lecture series.

Sporadically, a resident will work for 2-3 months on a clinical research project, culminating in a publication to be authored by the resident.

Fellows:

Former Director, Retinal Fellowship Program at Wilmer Eye Institute

Supervise 2 to 3 fellows, 3 days per week, in the management of retinal diseases in patients from my practice.

Sporadically, a fellow will work for 2-3 months on a clinical research project, culminating in a publication to be authored by the fellow (see for example, article by Dyer DS et al, *Am J Ophthalmol*, 1995).

Other:

School of Public Health and Hygiene: Participate in lecture to epidemiology students once per year.

Sporadic participation on a Thesis Committee for Ph.D. candidates at School of Public Health and Hygiene when topics involve retina (most recent PhD for 2002: [-----]).

Sporadically, a student in the School of Public Health and Hygiene will work on a clinical research project, culminating in a publication to be authored by the student ([-----]).

CLINICAL ACTIVITIES

NEIL M. BRESSLER, M.D.
CURRICULUM VITAE

National and international referral practice specializing in the management of medical retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusions), with specific reference to treatments for these conditions as well as designing and directing clinical trials evaluating new managements of these diseases.

ADMINISTRATIVE RESPONSIBILITIES:

UNIVERSITY SCHOOL OF MEDICINE ACTIVITIES

- Associate Professor Promotions Committee (1994 - 1998)
- Committee on Outside Interests (formerly Committee on Conflict of Interest): 2002 – present; Co-chair 2006-2007; currently Chair.

DEPARTMENTAL ACTIVITIES

Clinical Practice Advisory Committee (1989 - present)

Identification of clinical practice problems, such as incorrect billing by either the Chief Resident or the full-time faculty for professional fee visits or surgical billing; development of more efficient and informative pre-registration processes; development of better "time of service" payment mechanisms.

Chairman, Subcommittee on Electronic Patient Record for Wilmer Institute. (1995 -1997)

Resident Education Committee:

Serve in an advisory role to the Chief Resident to identify educational needs of the residency program, including the core curriculum. (1993 -1997)

Chairman, Wilmer Imaging Committee (2001- 2003)

DIVISIONAL ACTIVITIES

Chief, Retina Division
